TNF and anti-neutrophil cytoplasmic antibody-associated vasculitis: This finding elucidates why the initial prospective clinical trial demonstrated high remission rates in more severe AAV patients; that is, TNF-α blockade is effective in reducing inflammation and tissue damage in advanced stages of the disease, highlighting the importance of disease severity and timing in therapeutic efficacy.